Pathogenesis of lung cancer signalling pathways: Roadmap for therapies

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1485-1497

  Brambilla, E ^a   Gazdar, A ^b  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Lung cancer pathology; Molecular biology; Molecular genetics; Molecular pathology; Molecular therapy; Signal pathways

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ARF PROTEIN; CYCLIN D1; DEATH RECEPTOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; FAS LIGAND; HISTONE; HYBRID PROTEIN; MICRORNA; MITOCHONDRIAL DNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE LKB1; PROTEIN P14; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TELOMERASE; THYROID TRANSCRIPTION FACTOR 1;

APOPTOSIS; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SURVIVAL; CELL IMMORTALIZATION; CELL TRANSFORMATION; CHROMATIN; CHROMATIN STRUCTURE; DEREGULATION; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVATION; EPIGENETICS; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MITOCHONDRION; MOLECULAR BIOLOGY; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SMOKING; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; EPIGENESIS, GENETIC; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 69249132204     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00014009     Document Type: Review

References (141)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers- adifferentdisease. Nat Rev Cancer 2007; 7: 778-790.
3. Bach PB, Kelley MJ, Tate RC, et al. Screening for lung cancer: a review of the current literature. Chest 2003; 123: Suppl. 1, 72S-82S.
4. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-1771.
5. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
6. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898.
7. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
8. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54: 73-87.
9. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-1960.
10. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29: 633-639.
11. Song P, Sekhon HS, Fu XW, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 2008; 68: 4693-4700.
12. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
13. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194-1210.
14. Schwartz AG, Prysak GM, Bock CH, et al. The molecular epidemiology of lung cancer. Carcinogenesis 2007; 28: 507-518.
15. Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, et al. DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention. Cancer Lett 2008; 266: 60-72.
16. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 359-365.
17. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638-642.
18. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-637.
19. Young RP, Hopkins RJ, Hay BA, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008; 32: 1158-1164.
20. Amos CI, Xu W, Spitz MR. Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res 1999; 151: 3-12.
21. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004; 75: 460-474.
22. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-5557.
23. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
24. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-457.
25. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
26. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: Suppl. 4, S9-S15.
27. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262.
28. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
29. Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles "heal" of lung cancers? Trends Mol Med 2004; 10: 481-486.
30. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
31. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006; 118: 1426-1429.
32. Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 7001-7003.
33. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
34. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68: 6913-6921.
35. Moon A. Differential functions of Ras for malignant phenotypic conversion. Arch Pharm Res 2006; 29: 113-122.
36. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol 2006; 1: 7-9.
37. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246.
38. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
40. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
41. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
42. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
43. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007; 96: 857-863.
44. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
45. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-4882.
46. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
47. Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007; 2: Suppl. 2, S68-S76.
48. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
49. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005; 23: 5007-5018.
50. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005; 93: 1334-1340.
51. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
52. Zhang J, Iwanaga K, Choi KC, et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res 2008; 1: 201-207.
53. Yonesaka K, Zejnullahu K, Lindeman N, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-6973.
54. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50.
55. Gazdar AF, Minna JD. Deregulated EGFR signaling during lung cancer progression : mutations, amplicons, and autocrine loops. Cancer Prev Res 2008; 1: 156-160.
56. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007; 67: 4933-4939.
57. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007; 17: 31-39.
58. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7: 561-573.
59. Garnis C, Lockwood WW, Vucic E, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006; 118: 1556-1564.
60. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-17.
61. Meyerson M. Cancer: broken genes in solid tumours. Nature 2007; 448: 545-546.
62. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
63. Maeda Y, Dave V, Whitsett JA. Transcriptional control of lung morphogenesis. Physiol Rev 2007; 87: 219-244.
64. Tanaka H, Yanagisawa K, Shinjo K, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007; 67: 6007-6011.
65. Lockwood WW, Chari R, Coe BP, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008; 27: 4615-4624.
66. Gazzeri S, Brambilla E, Caron de Fromentel C, et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994; 58: 24-32.
67. Gazzeri S, Brambilla E, Chauvin C, et al. Analysis of the activation of the myc family oncogene and of its stability over time in xenografted human lung carcinomas. Cancer Res 1990; 50: 1566-1570.
68. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2009; 16: 1-12.
69. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609-1618.
70. Jeanmart M, Lantuejoul S, Fievet F, et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res 2003; 9: 2195-2203.
71. ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002; 21: 2750-2761.
72. Eymin B, Claverie P, Salon C, et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006; 26: 4339-4350.
73. Gazzeri S, Della Valle V, Chaussade L, et al. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998; 58: 3926-3931.
74. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 1975; 72: 5116-5120.
75. Gouyer V, Gazzeri S, Bolon I, et al. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998; 18: 188-196.
76. Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188: 351-360.
77. Brambilla E, Gazzeri S, Moro D, et al. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5: 243-250.
78. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
79. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-5918.
80. Herbst RS, Heymach JV, Lippman SM. Molecular origins of lung cancer. N Engl J Med 2008; 359: 1367-1380.
81. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007; 13: 7254-7263.
82. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941-1952.
83. Cheng EH, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-1968.
84. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004; 10: 4245s-4248s.
85. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
86. Viard-Leveugle I, Veyrenc S, French LE, et al. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003; 201: 268-277.
87. Eymin B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-1687.
88. Salon C, Eymin B, Micheau O, et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ 2006; 13: 260-272.
89. Merdzhanova G, Edmond V, De Seranno S, et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ 2008; 15: 1815-1823.
90. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol 2000; 18: 2626-2634.
91. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
92. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-913.
93. Nuciforo PG, Luise C, Capra M, et al. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007; 28: 2082-2088.
94. Nakanishi K, Kawai T, Kumaki F, et al. Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol 2002; 33: 697-702.
95. Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res 2005; 11: 2074-2082.
96. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
97. Lantuejoul S, Soria JC, Moro-Sibilot D, et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004; 90: 1222-1229.
98. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-7873.
99. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
100. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006; 3: e486.
101. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
102. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-255.
103. Zochbauer-Muller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003; 107: 612-616.
104. de Fraipont F, Moro-Sibilot D, Michelland S, et al. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 2005; 50: 199-209.
105. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-1128.
106. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005; 14: R85-R92.
107. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298.
108. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
109. Groth A, Rocha W, Verreault A, et al. Chromatin challenges during DNA replication and repair. Cell 2007; 128: 721-733.
110. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
111. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
112. Van Den Broeck A, Brambilla E, Moro-Sibilot D, et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 2008; 14: 7237-7245.
113. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007; 25: 4358-4364.
114. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 2007; 115: 1090-1106.
115. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008; 122: 969-977.
116. Boyd SD. Everything you wanted to know about small RNA but were afraid to ask. Lab Invest 2008; 88: 569-578.
117. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
118. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
119. Nana-Sinkam SP, Geraci MW. MicroRNA in lung cancer. J Thorac Oncol 2006; 1: 929-931.
120. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
121. Eder M, Scherr M. MicroRNA and lung cancer. N Engl J Med 2005; 352: 2446-2448.
122. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-9632.
123. He L, He X, Lowe SW, et al. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7: 819-822.
124. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307.
125. Harris KS, Zhang Z, McManus MT, et al. Dicer function is essential for lung epithelium morphogenesis. Proc Natl Acad Sci USA 2006; 103: 2208-2213.
126. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007; 67: 2345-2350.
127. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006; 25: 4663-4674.
128. Kagan J, Srivastava S. Mitochondria as a target for early detection and diagnosis of cancer. Crit Rev Clin Lab Sci 2005; 42: 453-472.
129. Zhou S, Kachhap S, Sun W, et al. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci USA 2007; 104: 7540-7545.
130. Sui G, Zhou S, Wang J, et al. Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol Cancer 2006; 5: 73.
131. Suzuki M, Toyooka S, Miyajima K, et al. Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res 2003; 9: 5636-5641.
132. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-827.
133. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
134. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002; 62: 3244-3250.
135. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24: 1679-1688.
136. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008; 27: 3635-3640.
137. Wisniewski JR. Mass spectrometry-based proteomics: principles, perspectives, and challenges. Arch Pathol Lab Med 2008; 132: 1566-1569.
138. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452: 571-579.
139. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 2008; 23: Suppl. 1, 78-84.
140. Saijo N. Advances in the treatment of non-small cell lung cancer. Cancer Treat Rev 2008; 34: 521-526.
141. Gridelli C. Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road. Curr Opin Oncol 2008; 20: 145-147.